PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy

Experimental Eye Research

Volumn 89, Issue 6, 2009, Pages 1028-1034

  Chen, Yihui ^a,b   Xu, Xun ^a   Sheng, Minjie ^b   Zhang, Xiaoyan ^b   Gu, Qing ^a   Zheng, Zhi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

asymmetric dimethylarginine; diabetic retinopathy; endothelium; reactive oxygen species; renin angiotensin system

Indexed keywords

ACETYLCYSTEINE; BENAZEPRIL; CYCLIC GMP; DIMETHYLARGININASE; DIMETHYLARGININASE I; DIMETHYLARGININASE II; DIPHENYLIODONIUM SALT; GLUCOSE; N(G),N(G) DIMETHYLARGININE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; REACTIVE OXYGEN METABOLITE; TELMISARTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; GLUCOSE INTAKE; HYPERGLYCEMIA; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA CAPILLARY; STREPTOZOCIN DIABETES; UPREGULATION;

AMIDOHYDROLASES; ANIMALS; ARGININE; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIC GMP; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; MALE; PROTEIN-ARGININE N-METHYLTRANSFERASES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; UP-REGULATION;

EID: 70350719223     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2009.09.004     Document Type: Article

References (44)

1. Abbasi F., Asagmi T., Cooke J.P., Lamendola C., McLaughlin T., Reaven G.M., Stuehlinger M., and Tsao P.S. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am. J. Cardiol. 88 (2001) 1201-1203
2. Beltowski J., and Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol. Rep. 58 (2006) 159-178
3. Benndorf R., Boger R.H., Ergun S., Steenpass A., and Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ. Res. 93 (2003) 438-447
4. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., Blaschke T.F., and Cooke J.P. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
5. Boger R.H., Sydow K., Borlak J., Thum T., Lenzen H., Schubert B., Tsikas D., and Bode-Boger S.M. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 87 (2000) 99-105
6. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46 (1995) 223-234
7. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26 (2003) 1589-1596
8. Cui Y., Xu X., Bi H., Zhu Q., Wu J., Xia X., Qiushi R., and Ho P.C. Expression modification of uncoupling proteins and MnSOD in retinal endothelial cells and pericytes induced by high glucose: the role of reactive oxygen species in diabetic retinopathy. Exp. Eye Res. 83 (2006) 807-816
9. Delles C., Schneider M.P., John S., Gekle M., and Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am. J. Hypertens. 15 (2002) 590-593
10. Fard A., Tuck C.H., Donis J.A., Sciacca R., Di Tullio M.R., Wu H.D., Bryant T.A., Chen N.T., Torres-Tamayo M., Ramasamy R., Berglund L., Ginsberg H.N., Homma S., and Cannon P.J. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2039-2044
11. Franken A.A., Derkx F.H., Schalekamp M.A., Man in t'Veld A.J., Hop W.C., van Rens E.H., and de Jong P.T. Association of high plasma prorenin with diabetic retinopathy. J. Hypertens. 6 (1988) S461-S463
12. Ito A., Egashira K., Narishige T., Muramatsu K., and Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ. J. 66 (2002) 811-815
13. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., and Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
14. Jia S.J., Jiang D.J., Hu C.P., Zhang X.H., Deng H.W., and Li Y.J. Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells. Vascul. Pharmacol. 44 (2006) 143-148
15. Jiang D.J., Jiang J.L., Tan G.S., Du Y.H., Xu K.P., and Li Y.J. Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn Schmiedebergs Arch. Pharmacol. 367 (2003) 600-606
16. Jiang J.L., Zhu H.Q., Chen Z., Xu H.Y., and Li Y.J. Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine level. Int. J. Cardiol. 101 (2005) 153-155
17. Kimoto M., Whitley G.S., Tsuji H., and Ogawa T. Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J. Biochem. 117 (1995) 237-238
18. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 (1998) 859-866
19. Lee A.Y., Chung S.K., and Chung S.S. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc. Natl. Acad. Sci. U S A 92 (1995) 2780-2784
20. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., Rossiter S., Anthony S., Madhani M., Selwood D., Smith C., Wojciak-Stothard B., Rudiger A., Stidwill R., McDonald N.Q., and Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 13 (2007) 198-203
21. Leiper J., and Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc. Res. 43 (1999) 542-548
22. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., Tsuji H., Reaven G.M., and Cooke J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
23. MacAllister R.J., Parry H., Kimoto M., Ogawa T., Russell R.J., Hodson H., Whitley G.S., and Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 119 (1996) 1533-1540
24. Malecki M.T., Undas A., Cyganek K., Mirkiewicz-Sieradzka B., Wolkow P., Osmenda G., Walus-Miarka M., Guzik T.J., and Sieradzki J. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes. Diabetes Care 30 (2007) 2899-2901
25. Murray-Rust J., Leiper J., McAlister M., Phelan J., Tilley S., Santa Maria J., Vallance P., and McDonald N. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat. Struct. Biol. 8 (2001) 679-683
26. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000) 787-790
27. Onozato M.L., Tojo A., Goto A., Fujita T., and Wilcox C.S. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 61 (2002) 186-194
28. Onozato M.L., Tojo A., Leiper J., Fujita T., Palm F., and Wilcox C.S. Expression of NG, NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 57 (2008) 172-180
29. Palm F., Buerk D.G., Carlsson P.O., Hansell P., and Liss P. Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats: effects on renal oxygenation and microcirculation. Diabetes 54 (2005) 3282-3287
30. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
31. Schulze F., Wesemann R., Schwedhelm E., Sydow K., Albsmeier J., Cooke J.P., and Boger R.H. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin. Chem. Lab. Med. 42 (2004) 1377-1383
32. Stuhlinger M.C., Tsao P.S., Her J.H., Kimoto M., Balint R.F., and Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104 (2001) 2569-2575
33. Suda O., Tsutsui M., Morishita T., Tasaki H., Ueno S., Nakata S., Tsujimoto T., Toyohira Y., Hayashida Y., Sasaguri Y., Ueta Y., Nakashima Y., and Yanagihara N. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of rennin-angiotensin system and oxidative stress. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1682-1688
34. Sugai M., Ohta A., Ogata Y., Nakanishi M., Ueno S., Kawata T., Saito N., and Tanaka Y. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr. J. 54 (2007) 303-309
35. Sydow K., and Munzel T. ADMA and oxidative stress. Atheroscler. Suppl. 4 (2003) 41-51
36. Sydow K., Schwedhelm E., Arakawa N., Bode-Boger S.M., Tsikas D., Hornig B., Frolich J.C., and Boger R.H. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins. Cardiovasc. Res. 57 (2003) 244-252
37. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., and Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27 (2004) 765-769
38. Tran C.T., Fox M.F., Vallance P., and Leiper J.M. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 68 (2000) 101-105
39. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
40. Wilkinson-Berka J.L. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol. 38 (2006) 752-765
41. Wong H.C., Boulton M., Marshall J., and Clark P. Growth of retinal capillary endothelia using pericyte conditioned medium. Invest. Ophthalmol. Vis. Sci. 28 (1987) 1767-1775
42. Yamagishi S., Amano S., Inagaki Y., Okamoto T., Inoue H., Takeuchi M., Choei H., Sasaki N., and Kikuchi S. Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation. Drugs Exp. Clin. Res. 29 (2003) 75-80
43. Zheng Z., Chen H., Ke G., Fan Y., Zou H., Sun X., Gu Q., Xu X., and Ho P.C. Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway. Diabetes 58 (2009) 954-964
44. Zheng Z., Chen H., Xu X., Li C., and Gu Q. Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy. Exp. Eye Res. 84 (2007) 745-752